Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

Arsenic Trioxide / adverse effects Arsenicals Humans Leukemia, Promyelocytic, Acute / diagnosis Neoplasm, Residual / diagnosis Oxides Recurrence Translocation, Genetic Tretinoin
APL ATRA plus ATO MRD monitoring

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 21 10 2021
medline: 15 4 2022
entrez: 20 10 2021
Statut: ppublish

Résumé

Acute promyelocytic leukemia (APL) is characterized by the chromosomal translocation

Identifiants

DOI: 10.1080/10428194.2021.1992757 PMID: 34668451
pubmed: 34668451
doi: 10.1080/10428194.2021.1992757
doi:

Substances chimiques

Arsenicals 0
Oxides 0
Tretinoin 5688UTC01R
Arsenic Trioxide S7V92P67HO

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

672-675

Auteurs

Jorge M Ramos Perez (JM)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Keyur P Patel (KP)

Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Sanam Loghavi (S)

Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Guillermo Garcia-Manero (G)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Gautam Borthakur (G)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID: 0000-0001-7679-6453

Elias Jabbour (E)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

William Wierda (W)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Sherry Pierce (S)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Mark Brandt (M)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Steven Kornblau (S)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Tapan Kadia (T)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Naval Daver (N)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Courtney D DiNardo (CD)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Nitin Jain (N)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Musa Yilmaz (M)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Nicholas Short (N)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Srdan Verstovsek (S)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID: 0000-0002-6912-8569

Alessandra Ferrajoli (A)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Michael Andreeff (M)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Marina Konopleva (M)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Daniel Rivera (D)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

David McCue (D)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Hagop M Kantarjian (HM)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Farhad Ravandi (F)

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID: 0000-0002-7621-377X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Trioxyde d'arsenic › Value of measurable residual disease...
questionsmedicales.fr › Composés chimiques organiques › Composés de l'arsenic › Value of measurable residual disease...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Value of measurable residual disease...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Leucémie aiguë promyélocytaire › Value of measurable residual disease...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Value of measurable residual disease...
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Oxydes › Value of measurable residual disease...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › Value of measurable residual disease...
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Translocation génétique › Value of measurable residual disease...
questionsmedicales.fr › Facteurs biologiques › Pigments biologiques › Caroténoïdes › Rétinoïdes › Trétinoïne › Value of measurable residual disease...